Policy Comments

The priority legislative and regulatory issues that the Cancer Policy Institute focuses on are driven by policy pillars that are centered around the values, needs, and preferences of individuals impacted by cancer. We work in conjunction with patients, patient advocacy organizations, medical associations, and other stakeholders to advance policies aimed at improving access to, affordability of, and quality of care across the cancer continuum.

Letter to HHS in support of Oregon's 1115 waiver and recommending a clear implementation plan to mitigate coverage loss.

Medicaid Section 1115 Waivers

Letter to HHS in response to Wisconsin's 1115 waiver opposing the imposition of premiums, lockouts, emergency department copayments and health risk assessment requirements.

Medicaid Section 1115 Waivers

Comments to HHS with recommendations for the National Provider Directory to ensure the database is a one-stop-shop for patients considering their provider and health plan choices based on robust, current and accurate information.

Access to Affordable, Comprehensive Care, Medicare, Medicaid, and Private Health Insurance Coverage, Surprise Medical Billing

Letter thanking Congresswomen Blunt Rochester for introducing The Preventive Services Early Action Act, which would make important reforms to the United State Preventive Services Task Force.

Access to Innovative Treatment

Comments to CMS on accessing healthcare and related challenges, understanding provider experiences, advancing health equity, and assessing the impact of waivers and flexibilities provided in response to the COVID-19 Public Health Emergency (PHE). These comments include challenges and recommendations.

Health Equity, Medicare, Medicaid, and Private Health Insurance Coverage

Comments to CMS in regard to protecting patients’ access to care at the end of the COVID-19 PHE. Including Medicaid, CHIP, and Basic Health Program beneficiaries.

Medicare, Medicaid, and Private Health Insurance Coverage

Letter addressing provisions that are important to informing patients of the expected costs associated with care they are seeking as a part of the No Surprises Act.

Surprise Medical Billing

Letter urging Congress to urge to enact the PASTEUR Act in an end of year package to address the growing crisis of antimicrobial resistance (AMR).

Access to Innovative Treatment

Letter to the Attorney General and DEA detailing short-term actions that can be taken to ensure patients continue to have access to telehealth treatment.


Comments to HHS with recommendations for extent, scope and nature of value assessment methods that discriminate on the basis of race, color, national origin, sex, age, or disability; the use of clinical algorithms in health care decision-making; and nondiscrimination requirements and enforcement.